← Back to work
Works cited by this work
199 works
Work: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang +17
Article20092 citationsABIThe role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu, Mien‐Chie Hung
Review article20162 citationsABITracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan +80
Article20172 citationsABIBiomarker concordance between primary colorectal cancer and its metastases
Dilraj Bhullar, Jorge Barriuso, S. Mullamitha +3
Review article20192 citationsABIPD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie +1
Review article20192 citationsABICRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38
Article20202 citationsABIMemory T cells: strategies for optimizing tumor immunotherapy
Qingjun Liu, Zhongjie Sun, Ligong Chen
Review article20202 citationsABICAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner
Review article20212 citationsABILipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Jinge Zhou, Lei Sun, Yujie Jia +8
Article20222 citationsABIImmunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Zaoqu Liu, Zhaokai Zhou, Qin Dang +4
Review article20222 citationsABIOvercoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute +4
Review article20222 citationsABIHypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors
Xiuxiu Zhu, Jun Chen, Wuling Li +8
Article20232 citationsABI